Methods: National representatives (NR) from all EU countries were invited to participate in the network, recruiting participating ‘high skilled NH’s’ (IPSE-project definition): either at least 5 NHs/country (voluntary basis) with a minimum of 250 eligible residents/PPS, or a randomly selected representative sample of NHs.
A national survey on NH characteristics, national/regional regulating mechanisms for AB use and infection control in NHs was set up, using a written standardised questionnaire completed by the NR from each participating country. Two consecutive PPS on AB-use were planned (April & November 2009) to measure the prevalence (one single day) of AB-use among residents present on the PPS-day for at least 24h. Antibacterials, antimycotics and tuberculostatics for systemic use and nasal decontamination of MRSA carriage were registered. A resident questionnaire collected individual determinants and characteristics of AB-treatment. An institutional questionnaire collected determinants for AB-use on NH-level and aggregated denominator data (risk factors & care load indicators) for the total NH-population. PPS data were collected by a local- or by an external surveyor. Paper questionnaires for optical reading were proposed. Data could also be entered using the specially developed web-based NH PPS software. Study tools were submitted to the Ethical committee. A written consent form was obtained from residents/proxy’s. Individual feedback reports were provided to participating NHs.Results: 21 EU countries responded to the national survey on NHs and their specific AB-policy characteristics. Furthermore, the NH network (19 countries) collected AB data in 301 NHs during the first European NH PPS. Conclusions: The PPS methodology appeared to be a useful, non labour-intensive tool and feasible at EU level. The national survey showed important structural and functional differences indicating that categorization of EU NHs will be an important challenge required for meaningful data comparisons.